IRF3 Knouckout SK-HEP-1 Polyclonal Cells is a CRISPR/Cas9-edited polyclonal cell population featuring targeted disruption of the IRF3 gene in the human liver adenocarcinoma cell line SK-HEP-1. This polyclonal knockout product provides a heterogeneous pool of gene-edited cells, avoiding clonal artifacts and enabling robust functional studies of IRF3-dependent pathways. The CRISPR/Cas9 system was employed to introduce loss-of-function mutations, generating a versatile model for interrogating IRF3 biology in an oncogenic hepatic background.
The SK-HEP-1 host cell line was originally established from the ascitic fluid of a patient diagnosed with liver adenocarcinoma. This cell line exhibits mesenchymal and invasive properties, making it a widely used model for studying liver cancer biology, including tumor invasion, metastasis, and hepatocarcinogenesis. SK-HEP-1 cells endogenously express components of immune signaling pathways, but the integration of CRISPR-mediated genetic modifications, such as IRF3 perturbation, expands their utility in dissecting tumor-intrinsic innate immune mechanisms.
IRF3 is a critical transcription factor for innate antiviral immunity. In unstimulated cells, IRF3 resides in the cytoplasm in a latent state. Upon activation of pattern recognition receptors such as RIG-I, MDA5, cGAS, TLR3, or TLR4, signaling converges on the kinases TBK1 and IKK??, which phosphorylate IRF3 at Ser386 and Ser396. This modification triggers dimerization, nuclear translocation, and association with coactivators CBP/p300 and NF-??B, leading to transcriptional induction of type I interferons (IFN-??, IFN-??) and interferon-stimulated genes (ISGs) like ISG15, OAS1, MX1, and CXCL10. IRF3 thus operates downstream of the adaptors MAVS, STING, and TRIF, and integrates signals from the RIG-I-like receptor, Toll-like receptor, and cGAS-STING pathways to establish an antiviral state.
In the context of SK-HEP-1 liver adenocarcinoma cells, IRF3 knockout enables investigation of how antiviral signaling intersects with hepatic oncogenesis and tumor-related immune responses. The mesenchymal and invasive nature of SK-HEP-1 provides a relevant backdrop for studying the role of IRF3 in tumor cell-autonomous innate immunity, the influence of interferon signaling on cancer cell proliferation and migration, and the potential crosstalk with pathways driving epithelial-mesenchymal transition. Given the established link between chronic viral hepatitis and liver cancer, this model is especially valuable for exploring IRF3-dependent mechanisms in viral oncogenesis and inflammation-driven hepatocarcinogenesis.
Key applications include mechanistic studies of hepatic innate immune responses to viral pathogens, functional analysis of interferon signaling in liver adenocarcinoma, dissection of IRF3-dependent transcriptional programs, and drug screening for modulators of the IRF3 pathway. Relevant experimental techniques encompass Western blotting for total and phospho-IRF3, RT-qPCR for IFN-?? and ISG mRNAs, IFN-?? promoter luciferase reporter assays, immunofluorescence for nuclear IRF3 localization, flow cytometry for intracellular cytokines, and co-immunoprecipitation of IRF3 with upstream kinases. Additionally, these cells are suitable for viral infection assays and chemosensitivity testing, supporting translational research in liver cancer immunology and antiviral therapy. For more information, please contact Ascent Research.
